Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Acadia Pharmaceuticals Inc.

< Previous 1 2 3 4 5 Next >
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.